Details of the Drug Reposition

General Information of This Drug (ID: DMUWFD8)

Drug Name
Sacituzumab govitecan   DMUWFD8
Synonyms
hRS7-SN38; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; UNII-M9BYU8XDQ6; hRS 7SN38; Satralizumab linker; IMMU 132; IMMU-132; M9BYU8XDQ6; 1491917-83-9; sacituzumab-govitecan; DA64T2C2IO; CYSTEINYL CL2A-SN-38; SN-38 CYSTEINYL CONJUGATE; DTXSID401335985; EX-A4354; GOVITECAN CYSTEINYL CONJUGATE; F82944; 1535963-91-7; 1796566-95-4
Drug Type
Antibody drug conjugate
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Approved [1]
Urothelial carcinoma DISRTNTN 2C92.0 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DISI0V1B 2C25 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website.
2 ClinicalTrials.gov (NCT05089734) Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. U.S.National Institutes of Health.